Form 4: Galectin Therapeutics Director Gilbert S. Omenn Reports Stock Option Grant
SEC Form 4 Filing
Director Gilbert S. Omenn reports the acquisition of stock options in Galectin Therapeutics, Inc.
Summary
- On January 23, 2025, Gilbert S. Omenn, a director of Galectin Therapeutics Inc., reported the acquisition of 60,000 stock options.
- The options, with an exercise price of $1.23, were granted under the company's 2019 Omnibus Equity Incentive Plan.
- These options vest 100% on December 31, 2025, and expire on January 23, 2035.
- Following the transaction, Omenn directly owns 60,000 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the director.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/23/2025 | Date of transaction: Director acquired stock options. |
| 12/31/2025 | Vesting date: Options vest 100%. |
| 01/23/2035 | Expiration date: Options expire. |
| 01/27/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.